Is TRT Covered by Insurance? What to Know

Is TRT covered by insurance? In most cases, testosterone replacement therapy can be covered, but it is highly plan-specific and usually depends on whether your record documents a clinical diagnosis of hypogonadism (low testosterone). Coverage is generally more likely when there are persistent signs or symptoms of androgen deficiency plus two low early-morning blood tests, and far less likely when therapy is framed as anti-aging or cosmetic. This article explains, as general US-market context, what payers tend to look for. It is educational information, not medical advice, and not a Revive coverage promise.

What does “covered” actually mean for TRT?

“Covered” means your plan agrees to pay some share of an FDA-approved testosterone product after you meet its medical-necessity criteria, often including prior authorization. It is not a yes/no rule that applies everywhere; the same prescription can be covered under one plan and denied under another. Deductibles, formularies, step therapy, and prior-authorization timelines all differ, so the only reliable answer comes from your own plan documents or member services line.

It also helps to separate two questions people tend to merge: is the drug medically appropriate for me, and will my plan pay for it. A licensed provider determines the first through evaluation; your insurer decides the second based on its policy. The two are connected, because payers generally tie coverage to the same diagnostic standards clinicians use.

What do insurers typically require to cover TRT?

Commercial payers generally anchor coverage to a documented hypogonadism diagnosis. As a representative example, the Cigna National Formulary testosterone prior-authorization policy (review date 11/19/2025) recommends prior authorization and, for initial therapy, requires all of: persistent pretreatment signs or symptoms of androgen deficiency; two pretreatment serum testosterone measurements each taken in the morning on two separate days; and both levels low by laboratory reference values. That same policy lists use “to enhance athletic performance” as not medically necessary.

This mirrors the clinical guidelines. The American Urological Association 2018 guideline states a total testosterone below 300 ng/dL is a reasonable cut-off supporting a diagnosis of low testosterone, made only after two early-morning measurements on separate occasions together with symptoms or signs. The Endocrine Society 2018 guideline similarly recommends diagnosing hypogonadism only with symptoms and consistently low testosterone, starting with a fasting morning total testosterone confirmed by a repeat fasting morning measurement. Note that these are diagnostic thresholds, not automatic coverage triggers; meeting them supports a diagnosis but does not guarantee any payer will approve.

What payers/guidelines look for	Detail (general context)	Source
Documented symptoms	Persistent signs/symptoms of androgen deficiency	Cigna PA; AUA 2018; Endocrine Society 2018
Two early-morning tests	Two serum testosterone tests on separate days, both low	Cigna PA; AUA 2018; Endocrine Society 2018
Diagnostic threshold	Total testosterone below 300 ng/dL is a reasonable cut-off	AUA 2018
Prior authorization	Often recommended/required before coverage	Cigna PA
Commonly excluded	Athletic performance; cosmetic/anti-aging; mild fatigue; age-related decline alone	Cigna PA; general payer practice

Why would an insurer deny TRT?

Denials usually trace back to indication and documentation. Insurers commonly deny testosterone when it is prescribed for cosmetic or anti-aging purposes, athletic-performance enhancement, mild fatigue, or general age-related decline rather than a documented FDA-approved medical indication such as diagnosed hypogonadism. Missing or incomplete records, such as only one testosterone test, an afternoon draw, or no symptom documentation, are also frequent reasons a prior authorization fails.

That is why an evaluation with a licensed provider matters. Proper diagnosis is not just clinically appropriate, it is also what most payers require to consider coverage at all. If you are weighing options, our overview of signs you may need hormone replacement therapy and our TRT dosage guide explain how diagnosis and treatment are typically approached.

Are compounded and cash-pay TRT options covered?

Often, no. Compounded testosterone and many cash-pay telehealth routes are frequently not covered because compounded drugs are not FDA-approved. According to the FDA, compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness, or quality before they are marketed. That non-approval is a common reason payers exclude them.

If you are on Medicare, Part D may cover self-administered testosterone, subject to your plan’s formulary and tier and a determination that it is medically necessary. Compounded preparations, however, are commonly excluded: compounded drugs are not FDA-approved, and under the CMS Medicare Prescription Drug Benefit Manual (Chapter 6) a compounded product is treated as a covered Part D drug only to the extent its ingredients independently meet the definition of a Part D drug and are themselves on the plan’s formulary. It is worth distinguishing FDA-approved bioidentical products from compounded bioidentical hormone therapy (cBHT): the 2020 NASEM report found a lack of high-quality evidence of safety and effectiveness for cBHT and recommended restricting its use to patients allergic to an ingredient in an FDA-approved product or who need a dosage form not available in one. Never assume cBHT is FDA-approved or proven safe. You can read more in our overview of bioidentical hormones, pros and cons.

Some patients explore TRT-adjuncts such as hCG or enclomiphene. These are compounded and not FDA-approved, are used off-label in men, and are not testosterone-replacement products themselves; the AUA notes that exogenous testosterone impairs sperm production, which is one reason fertility-minded patients ask about alternatives. If that is your situation, see enclomiphene vs TRT and hCG with TRT for context, and discuss coverage and appropriateness with a licensed provider, since compounded options are frequently not reimbursed.

Is testosterone a controlled substance, and what monitoring is required?

Yes. Testosterone is a DEA Schedule III controlled substance under the Anabolic Steroids Control Act of 1990, and the DEA classifies anabolic steroids, including testosterone, as Schedule III, so possession or distribution without a valid prescription is illegal. That means TRT always requires a valid prescription, a diagnosis, and ongoing monitoring.

Monitoring typically includes hemoglobin/hematocrit (the AUA notes a hematocrit of 54% or greater warrants intervention such as dose reduction or temporary discontinuation), PSA in men over 40, and blood pressure. On February 28, 2025, the FDA issued class-wide labeling changes for testosterone products, adding a blood-pressure warning after ambulatory blood pressure monitoring studies confirmed a class-wide increase in blood pressure. For cardiovascular safety context in diagnosed men, the TRAVERSE trial (5,246 men aged 45–80 with cardiovascular disease or high risk, hypogonadal symptoms, and two fasting testosterone levels below 300 ng/dL) reported a first major adverse cardiac event in 7.0% on testosterone versus 7.3% on placebo (HR 0.96, 95% CI 0.78–1.17). These are safety findings, not coverage or efficacy claims. For more on timelines, see how long TRT takes to work.

How can I check whether my plan covers TRT?

Start with your plan documents and member services. Practical steps that tend to help: ask whether FDA-approved testosterone is on your formulary and at what tier; ask if prior authorization or step therapy applies; confirm what diagnostic documentation is needed (symptoms plus two low early-morning tests is the common standard); and ask whether compounded preparations are excluded. If a claim is denied, ask about the appeals process, since denials are sometimes reversed when documentation is completed.

Cost is a separate question from coverage and varies widely by plan, product, and pharmacy. We discuss general US-market cost context, clearly not Revive pricing, in what does TRT cost. For background on the legal classification, see is testosterone a controlled substance, and for finding care, where to get TRT.

Frequently asked questions

Is TRT covered by insurance?

It can be, but coverage is plan-specific and is generally more likely with a documented hypogonadism diagnosis (persistent symptoms plus two low early-morning testosterone tests). Many plans require prior authorization and cover only FDA-approved products. Insurers commonly deny use framed as anti-aging, cosmetic, mild fatigue, or general age-related decline. Always verify benefits, prior-authorization rules, and formulary status with your own plan; this is general context, not a coverage guarantee.

What documentation do insurers usually require for TRT?

As a representative example, the Cigna National Formulary policy (reviewed 11/19/2025) requires, for initial therapy, persistent symptoms of androgen deficiency plus two morning serum testosterone tests on separate days, both low. This mirrors the AUA 2018 and Endocrine Society 2018 guidelines, which use a below-300 ng/dL cut-off as one diagnostic factor. Requirements vary by plan, so confirm yours directly.

Why might my insurer deny TRT?

Common reasons include prescribing for cosmetic/anti-aging, athletic performance, mild fatigue, or age-related decline rather than diagnosed hypogonadism, as well as incomplete documentation such as a single test, an afternoon draw, or no recorded symptoms. If denied, ask about the appeals process; coverage decisions vary by plan.

Does insurance cover compounded testosterone?

Often not. Compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing, which is a frequent reason payers exclude them. For Medicare, Part D may cover self-administered testosterone subject to the plan’s formulary and tier and a medical-necessity determination, but under CMS rules a compounded product is covered only to the extent its qualifying ingredients are themselves covered formulary drugs, so compounded preparations are commonly excluded. Check your specific plan.

Is testosterone a controlled substance?

Yes. Testosterone is a DEA Schedule III controlled substance under the Anabolic Steroids Control Act of 1990. It requires a valid prescription, a diagnosis, and ongoing monitoring, including hemoglobin/hematocrit, PSA in men over 40, and blood pressure. In 2025 the FDA added a blood-pressure warning to testosterone product labeling.

Does meeting the 300 ng/dL threshold guarantee coverage?

No. A total testosterone below 300 ng/dL on two early-morning tests, with symptoms, is a guideline diagnostic threshold for hypogonadism, not an automatic coverage trigger. It supports a diagnosis, but each plan applies its own medical-necessity criteria and prior-authorization rules, so meeting it does not guarantee approval.